

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP Journal of Nutrition, Metabolism and Health Science

Journal homepage: <https://www.jnmhs.com/>

## Review Article

# Awareness of medical issues in health sciences and in scientific technological education

V Rama Raju <sup>1,\*</sup>

<sup>1</sup>Jawaharlal Nehru Technological University/ CMR College of Engineering & Technology, Telangana, India



## ARTICLE INFO

### Article history:

Received 10-04-2023

Accepted 18-05-2023

Available online 08-09-2023

### Keywords:

Apnea

Insomnia

Quality of life

Parkinson disease

Rapid (quick

Eye movement sleep) behavior

disorder(RBD)

Restless legs syndrome(RLS)

Sleepapneasyndrome(SAS)

## ABSTRACT

In humans' quality of life (QoL) sleep disorders are familiar problems damaging the quality-of-life (QoL) of persons affected with Parkinson's disease (PD). These are repeatedly undervalued. The causes of these disturbances are multi-factorial as well and also involve nightly (nocturnal-motor) disturbances, nocturia, depressive/miserable axial-symptoms, and use of the medicine (medication-use) under medical administration or management/ medical management. The comorbidity is the concurrent (asynchronous) presence of two or more diseases or medical conditions in a patient and thus age and comorbidity may be risk factors for poor outcome. A disease or medical condition that is simultaneously present with another or others in a patient. Thence patients with cardiovascular or renal comorbidities. Comorbidity of Parkinson's through sleep apnea insomnia-syndrome, restless-legs-syndrome(RLS), rapid-eye-movement(REM) sleep-behavior disorders, blepharospasms or circadian eye ball movement cycle-disruption as well as outcomes are in (impaired)decreased sleep. Furthermore, the connection-of-serotonergic(CoS), noradrenergic, plus cholinergic-neurons (neuronal or neural) within the brain-stem region as a disease-connected variative influences to (impaired) decreased sleep structures.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Human life is becoming sandwiched in dilemma. Whether to opt for allopathic or homeopathic. In this study we show that therapeutics are the best procedures. Parkinson's disease (PD) is a neuro degenerative disorder described by the cardinal motor symptoms like akinesia/bradykinesia, tremor, rigidity, plus impaired postural-instabilities/reflexes that are due to de generation of dopamine dopaminergic neurons within the substantia nigra pars compacta and pars reticulata (SN,pc,pr).

Nonetheless, the pathological course-of the disease has been diagnosed/identified to be highly-large, relating the 'sero-tonin-ergic', 'nora-dren-ergic', and 'cholin-ergic' systems.<sup>1</sup> Therefore, these (the circuit-systems) act as a

functional-role within the growth and expansion of the non-motoric feature-manifestations/symptoms usually examined in Parkinson's.

For instance, apnea, insomnia sleep—disturbances like sleepless nights, restlessness, cognitive-depression, cognitive impairment, olfactive/olfactory disfunction, 'cognitive-impairments', 'fatigues', plus "autonomic-dysfunctions" as well.<sup>2</sup>

Frequency (incidence or prevalence) reaching 45% to 92% and these disturbances are amongst the maximum mutual non-motor-symptoms, they can interfere with patients' 'quality-of-life' (QoL).<sup>2-5</sup> An assortment of factors, involving 'nightmare/nocturnal motoric symptoms', neuro-psychiatric symptoms, cognitive-dementia, dopaminergic prescription-medications with dopaminergic.<sup>6</sup>

\* Corresponding author.

E-mail address: [drvenkateshwararr@gmail.com](mailto:drvenkateshwararr@gmail.com) (V. Rama Raju).

Comorbidity with sleep-apnea-syndrome(SAS), restless-legs syndrome(RLS), and rapid(quick, eye movement sleep) behavior disorder(R.B.D) is frequently detected, confusing and then apnea concerned to Parkinson's. The "orexin system" might have implicated in those diseased conditions, and thereby leading to the daylight lassitude and tiredness separate(unrelated) of reduced nap circumstances and situations. The R.B.D prior or parallelly synchronized through the disease has customary consideration, however, whether R.B.D and Parkinson's are produced with an analogous neuro degenerative process remnants not yet known.

The estimate plus medication of apnea/sleep-disorders in Parkinson's are of significant value due to their -Ve (negative) effect on the QoL. The advantage of the nap-use (sleep-benefit) of enhanced the early -morning hours motoric functioning prior medicine consumption is frequently stated through some Parkinson diseased conditions.<sup>7</sup>

Previous studies<sup>8,9</sup> and<sup>10</sup> showed that L-Dopa (i.e.,levodopa) medication absorptions plus poly-somnographic(PSG) results were analogous amid the Parkinson's with and without napping or snoozing advantage yet that Parkinson's through nap advantages showed a variety of response and retort outline/profile to the L-Dopa; the degree of motor decline and worsening following the L-Dopa consumption(intake) was higher in Parkinson's through the napping or snoozing advantages than in patients deprived of it exclusive of it.<sup>8</sup>

Biased views (i.e.,subjective-perceptions) and/or 'sensory-mechanisms' might play a role within the nap-advantage in Parkinson's. On the other hand, the outcome of nap deficiency over the motor act is polemic, debatable, controversial, and contentious.<sup>9</sup> This study examine the modern literature regarding "sleep-disorders" within Parkinson's.

## 2. Pathophysiology-of-Insomnia and Extremely Daylight Sleeping (Daylight napper)

The resultant of poly-somno-graphy(PSG) demos/records, data acquisitions/recordings transformed nap-structure has been examined in Parkinson's, n for instance, a reduction in the measure of non-rapid eye-movement ('NREM') nap phases three plus four as well as the REM sleeps.<sup>11</sup>

The disintegration or deterioration (degeneration) of "cholinergic-neurons" within basal 'fore-brain' plus 'brain-stem' containing the 'pedunculo-pontine-nucleus'(PPN) plus 'noradrenergic-neurons' inside the point coeruleus outcomes within the dis orders-of-REM sleep, plus a 'loss-of-serotonergic' cells and neurons inside the raphe (raphe)nucleus basis is linked through the decrease within the quantity of sluggish wave nap or snooze (slow wave sleep).<sup>12</sup>

Apart from this the 'orex-in' as well as "histamine-systems", these cells within brain-stem function as "arousal-movement-systems" which sustain sleeplessness, also disorder of these neural-cells (the neurons) indicates to extreme daylight lassitude or tiredness.

In Parkinson's, a loss-of "orexinergiccell-neurons" inside the lateral segment of the posterior hypo thalamus(PHT)<sup>13</sup> plus a decrease inside the numerous A10dopaminergic-neurons in the adaxial/ventral-tegmental-area VTA<sup>14-23</sup> have been engaged inside condensed impatience.

## 3. Restlessness Sleeplessness Insomnia

According to the studies, the insomnia is defined as "a disorder of the developing signs and symptoms: difficulty falling- numb, problem in continuing napping, without any delay involuntarily awakening, or non-refreshing nap which occurs in spite of sufficient chances for nap.

It's a general snooze or doze -disorder which may make it firm or stable to fall numb and insensible(asleep), tough and stiff to stay numb, or it might reason you to awaken a head of time in advance hastily plus unable to resume or continue with the napping. However, one might yet feel or sense exhausted when gets up.


Cases with insomnia are largely linked to very insignificant napping problems, weaknesses, cognitive dementia, and decline, depression, sadness, hopelessness, anxiety, 'lack-of-exercise' physio therapic problems, constant-illness' and/or positive medicine. The signs and symptoms or syndromes might involve problem collapsing or stopping sleeping plus unfeeling well-relaxed.

The therapy or medical management for insomnia involves enhancing the habits of the sleep, 'behavioral-therapy' plus distinguishing as well as discussing fundamental causes and/or causal reasons. The napping pills are taken however must be examined for dyskinesias like side-effects, for instance, memory, cognition, speech, etc.

Daylight losses linked to nocturnal dark-nightmares difficulties in sleepings have noted.<sup>5</sup> In a community-based study, sleeping starting was noted which is similar to in all the groups, however the Parkinson's moaned of more sleeping destruction contrasted through diabetic-conditions and/or controls.<sup>5</sup>

In Parkinson's, apnea, insomnia ("difficulty-staying-asleep") shows to be a familiar form-of-insomnia which is often affected thru nightly motoric disorders<sup>24,25</sup> The Fig 1 depicts the main reasons-of-insomnia, main-causes of insomnia examined within the Parkinson's.<sup>3,25-29</sup>

It's a usual problem with nocturia in general and in particular. Nearly more than 82% of patients showed three and more incidences of nocturia throughout the night affected through excess incontinency plus a 'bursting-bladder'.<sup>4</sup> If at all nocturia is noticed to be concerned



**Fig. 1:** The principal reasons of insomnia plus its “causal-factors”.

to wearing off signs, so switching medical management prescriptions to administer a long lasting acting the “dopamine-agonist” prior to sleep time might be favorable. Here, the testing’s such as urologic is advised this is because of nocturia might be correlated through standard “aging-process” or basic urological infections/diseases. The “nocturnal-motoric-symptoms” are due to the ‘hypo-dopaminergic-state’, for instance Bradykinesia plus intensified motoric-tremor as well as rigidity postural instability, also hyper-dopaminergic-state(HDS), for instance L-Dopa- correlated side-effects.<sup>30–32</sup>

Through distinction, a decrease inside the dosage of dopamine medicines might be useful and the results i.e., outcomes are also better for the feature manifestations linked through the “hyper dopaminergic state”.

#### 4. Extremely Daylight Lassitude Drowsiness

Following the study (1999-2000) quantified and also specified that abrupt and sudden-onset/ unexpected-onset the sleep occurrences (or episodes) are connected through vehicular technological accidents (during motor bike driving, etc) in patients who consume “non-er-got dopamine-agonists”,<sup>33</sup> and the connotation of “extreme-daylight-sleepiness” (‘EDS’) or nap events occurring through dopamine medication has developed an emphasis of care. Almost 18%–52% of patients informed to exhibit the “EDS”<sup>34–36</sup> An extraordinary ep-worth-sleepiness-scale(“ESS”) scoring, and sex (gender male) level or rank, longer duration of the disease is longer, as well as higher diseases and disorders seriousness have examined to be linked through the “EDS”.<sup>34,35,37</sup> Like the analogous to the insomnia experiential with in the Parkinson diseased conditions, numerous-factors’ are connected thru the “EDS”: reduced stimulation-systems’ and apart from that to the diseases processes, dopaminergic management, nocturnal turbulences, followed by simultaneous and also synchronized main napping disorders like ‘SAS’, ‘RBD’, as well as ‘RLS’ are supposed to be ‘causal-

factors’. Furthermore, “narcole-psy-like” signs and feature-manifestation-symptoms have been studied in a number of Parkinson’s through the Parkinson diseased conditions. Daylight tiredness or napping events demonstrating a petite nap latency(inactivity), petite napping on-set REM duration, also reduced ‘orex-in’ level-ranks are goals of diseased conditions’ nocturnal-nap-conditions.<sup>38–43</sup>

Numerous studies have demonstrated that consuming the dopamine agonists, i.e., L-Dopa is related through heightened daylight tiredness in diseased conditions particularly Parkinson’s<sup>34–37,44,45</sup>; yet, several supplementary experiments have diminished to enhance this considerable and paramount correlation,<sup>46,47</sup> Till date, whether identifiable dopamine agonists are linked through napness is however not yet clear.<sup>34,35,45</sup> Quick on-set-sleep episodes during driving have been 3.8%–22.8% of diseased conditions as well linked through the ‘high-score’ over the “ESS”<sup>34,37,47</sup> This outcome results reveal that the diseased conditions through larger ESS- scores are at consequence meant for undergoing nap events during driving with vehicular technology (motor-bike or four-wheeler).

#### 5. Conclusions

Extreme and unnecessary day time drowsiness sleepiness, tiredness is not just auxiliary to nocturnal disturbances or dopaminergic-medication (typically levodopa, carbidopa, or alpha-synuclein) simply may because of autonomous mechanisms linked to damages or impairments or losses in ascending arousal-system(AAS) therefore the orex-in- system (Ois). Remarkably, various modern lines-of-evidence indicate that a robust connection amongst REM sleep behavioral-disorder also risk-of-neuro (RIN) degenerative diseases for instance Parkinson disease (PD). This study focus on the disturbances in human subjects particularly on Parkinson’s movement disorders and other movement disorders.

The ‘sleep-disorders’ might happen during speedy phases of the patients especially Parkinson diseased conditions as well as the degrade as the syndrome developments. The deteriorating of the napping-sleep transpires in a way analogous to the development of motoric and non-motoric cognitive-dementias and cognitive- impairments, as well as the sorrow”, that encourages the idea-concept that chronic mechanisms as well as damages of the “arousal-system” plus structure-of-sleep play a pivotal role.

#### 6. Source of Funding

None.


#### 7. Conflict of Interest

None.

## References

1. Jellinger KA. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. *Mol Chem- ical Neuropathol.* 1991;14(3):153–97.
2. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. *Move Dis.* 2009;24(11):1641–9.
3. Kumar S. Sleep disorders in Parkinson's disease, Movement Disorders,. *Mov Disord.* 2002;17(4):775–81.
4. Lees AJ. The nighttime problems of Parkinson's disease. *Clin Neu- Ropharmacol.* 1988;11(6):512–9.
5. Tandberg E. A community- based study of sleep disorders in patients with Parkinson's disease. *Mov Dis.* 1998;13(6):895–9.
6. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. *Neurol.* 2005;64(12):12–20.
7. Merello M. Sleep benefit in Parkinson's disease. *Mov Dis.* 1997;12(4):506–8.
8. Ho BE. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. *Neurology.* 1998;50(5):1332–9.
9. gl BH. Effect of sleep deprivation on motor per- formance in patients with parkinson's disease. *Mov Dis.* 2001;16(4):616–21.
10. gl BH. Scales to assess sleep impairment in Parkinson's disease: critique and recommen- dations. *Mov Dis.* 2010;25(16):2704–16.
11. Petit D. Sleep and quantitative EEG in neurodegenera- tive disorders. *J Psychosom Res.* 2004;56(5):487–96.
12. Diederich NJ. Sleep disturbances in Parkinson's disease, in *Sleep and Movement Disorders.* Chokroverty S, Hening WA, Walters AS, editors. Elsevier Science, Philadelphia, Pa, USA.; 2003. p. 478–88.
13. Fronczek R. Hypocretin (orexin) loss in Parkinson's disease. *Brain.* 2007;130(6):1577–85.
14. Rye DB. The two faces of Eve: dopamine's modulation of wakefulness and sleep. *Neurology.* 2004;63(3):2–7.
15. Schwartz JRL. Neurophysiology of sleep and wakefulness: basic science and clinical implications. *Curr Neuroparmacol.* 2008;6(4):367–78.
16. Lu J, Zhou TC. Identification of wake- active dopaminergic neurons in the ventral periaqueductal gray matter. *J Neurosci.* 2006;26(1):193–202.
17. Decock VC. Sleep disturbances in patients with parkinsonism. *Nat Clin Pract Neurol.* 2008;4(5):254–66.
18. Monti JM. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. *Psychopharmacology.* 1988;95(3):395–400.
19. Manni R. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. *Sleep Med.* 2004;5(2):189–93.
20. Chaudhuri KR. Dopamine receptor agonists and sleep disturbances in Parkinson's disease. *Parkinsonism Related Dis.* 2010;15:101–4.
21. Ferreira JJ. Effect of ropinirole on sleep onset: a randomized, placebo- controlled study in healthy volunteers. *Neurol.* 2002;58(3):460–2.
22. Arnulf I. Parkinson's disease and sleepiness: an integral part of PD. *Neurology.* 2002;58(7):1019–24.
23. Cantor CR. Dopamine agonists and sleep in Parkinson's disease. *Neurology.* 2002;58(4):71–8.
24. Chaudhuri KR. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 2002;73(6):629–35.
25. Suzuki K. Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale. *Mov Dis.* 2007;22(9):1245–51.
26. Chaudhuri KR. Clinical assess- ment of nocturnal disability in Parkinson's disease: the Parkinson's. *Disease Sleep Scale.* 2004;63(8):17–20.
27. Gjerstad MD. Insomnia in Parkinson's disease: frequency and progression over time. *J Neurol Neurosurg Psychiatry.* 2007;78(5):476–9.
28. Dowling GA. Melatonin for sleep disturbances in Parkinson's disease. *Sleep Med.* 2005;6(5):459–66.
29. Abe K. A hypnotic drug for sleep disturbances in patients with Parkinson's disease. *Brain Nerve.* 2005;57(4):301–5.
30. Trenkwalder C. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo- controlled study (RECOVER). *Mov Dis.* 2011;26(1):90–9.
31. Reuter I. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. *Acta Neurologica Scandinavica.* 1999;100(3):163–7.
32. Arnulf I. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. *Neurology.* 2000;55(11):1732–4.
33. Frucht S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. *Neurology.* 1999;52(9):1908–10.
34. Ondo WG. Daytime sleepiness and other sleep disorders in Parkinson's disease. *Neurology.* 2001;57(8):1392–6.
35. Suzuki K. Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. *J Neurol Sci.* 2008;271(1- 2):47–52.
36. Tandberg E. Excessive day- time sleepiness and sleep benefit in Parkinson's disease: a community-based study. *Mov Dis.* 1999;14(6):922–7.
37. Tan EK. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex- matched controls. *Neurology.* 2002;58(3):465–8.
38. Arnulf I. Abnormal sleep and sleepiness in Parkinson's disease. *Curr Opin Neurol.* 2008;21(4):472–7.
39. Overeem S. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. *Curr Opin Neurol.* 2002;15(6):739–45.
40. Yasui K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. *J Neurol Sci.* 2006;250(1-2):120–3.
41. Thannickal TC. Hypocretin (orexin) cell loss in Parkinson's disease. *Brain.* 2007;130(6):1586–95.
42. Baumann CR. Parkin- son's disease, sleepiness and hypocretin/orexin. *Brain.* 2008;131(3):91. doi:10.1093/brain/awm220.
43. Compta Y. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. *Brain.* 2009;132(12):3308–17.
44. Brodsky MA. Sleepiness in Parkinson's disease: a controlled study. *Mov Dis.* 2003;18(6):668–72.
45. Paus S. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. *Mov Dis.* 2003;18(6):659–67.
46. Furumoto H. Excessive daytime somnolence in Japanese patients with Parkinson's disease. *Eur J Neurol.* 2004;11(8):535–40.
47. Hobson DE. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. *J Am Med Association.* 2002;287(4):455–63.

## Author biography

V Rama Raju, Professor  <https://orcid.org/0000-0003-0289-0724>

**Cite this article:** Rama Raju V. Awareness of medical issues in health sciences and in scientific technological education. *IP J Nutr Metab Health Sci* 2023;6(3):106-109.